Compare Bristol-Myers Squibb Co (BMY) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.61 (market cap $129.94B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals.
| BMY | FLRN | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $65.89 | $30.86 |
52-Week Low | $42.60 | $30.65 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
